Johnson & Johnson (JNJ): Operating Cash Flow
$24.53B
Year ended 2025-12-28
$26.16B
Trailing 12 months to 2026-09-27
+5.0%
3-year compound annual growth
+0.8%
5-year compound annual growth
+2.3%
10-year compound annual growth
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-28 | $24.53B | +1.1% | 2026-02-11, From 2024-12-30 |
| 2024-12-29 | $24.27B | +6.5% | 2026-02-11, From 2024-01-01 |
| 2023-12-31 | $22.79B | +7.5% | 2026-02-11, From 2023-01-02 |
| 2023-01-01, Fiscal 2022 | $21.19B | -9.5% | 2025-02-13, From 2022-01-03 |
| 2022-01-02, Fiscal 2021 | $23.41B | -0.5% | 2024-02-16, From 2021-01-04 |
| 2021-01-03, Fiscal 2020 | $23.54B | +0.5% | 2023-02-16, From 2019-12-30 |
| 2019-12-29 | $23.42B | +5.5% | 2022-02-17, From 2018-12-31 |
| 2018-12-30 | $22.20B | +5.4% | 2021-02-22, From 2018-01-01 |
| 2017-12-31 | $21.06B | +12.2% | 2020-02-18, From 2017-01-02 |
| 2017-01-01, Fiscal 2016 | $18.77B | -4.1% | 2019-02-20, From 2016-01-04 |
| 2016-01-03, Fiscal 2015 | $19.57B | +4.6% | 2018-02-21, From 2014-12-29 |
| 2014-12-28 | $18.71B | n/c | 2017-02-27, From 2013-12-30 |
| 2013-12-29 | $17.41B | +13.1% | 2016-02-24, From 2012-12-31 |
| 2012-12-30 | $15.40B | +7.7% | 2015-02-24, From 2012-01-02 |
| 2012-01-01, Fiscal 2011 | $14.30B | -12.7% | 2014-02-21, From 2011-01-03 |
| 2011-01-02, Fiscal 2010 | $16.39B | -1.1% | 2013-02-22, From 2010-01-04 |
| 2010-01-03, Fiscal 2009 | $16.57B | +10.7% | 2012-02-23, From 2008-12-29 |
| 2008-12-28 | $14.97B | -0.3% | 2011-02-25, From 2007-12-31 |
| 2007-12-30 | $15.02B | n/a | 2010-03-01, From 2007-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Johnson & Johnson (JNJ) | 2025-12-28 | $24.53B | +1.1% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $16.81B | +90.7% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $16.47B | -23.3% |
| Pfizer Inc (PFE) | 2025-12-31 | $11.70B | -8.2% |
| AbbVie Inc. (ABBV) | 2025-12-31 | $19.03B | +1.2% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $14.16B | -6.8% |
| Abbott Laboratories (ABT) | 2025-12-31 | $9.57B | +11.8% |
| Teva Pharmaceutical Industries Ltd (TEVA) | 2025-12-31 | $1.65B | +32.2% |
| Regeneron Pharmaceuticals, Inc. (REGN) | 2025-12-31 | $4.98B | +12.6% |
Compare JNJ, LLY, MRK, PFE side by side · Screen every company in Pharmaceutical Preparations ↗